# Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

> **NCT05052554** · PHASE1 · WITHDRAWN · sponsor: **ProQR Therapeutics**

## Conditions studied

- Fuchs Endothelial Corneal Dystrophy
- FECD3
- Corneal Diseases
- LRS
- Descemet's Membrane Disorder

## Interventions

- **DRUG:** QR-504a

## Key facts

- **NCT ID:** NCT05052554
- **Lead sponsor:** ProQR Therapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-08-10
- **Primary completion:** 2022-04-12
- **Final completion:** 2022-04-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** No patients
- **Last updated:** 2022-05-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05052554

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05052554, "Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT05052554. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*